This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
Age range
19 Years – 80 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Tumor Marker Levels
Timeframe: Baseline and annually for up to 5 years after enrollment in the long-term follow-up study.
Serious Adverse Events
Timeframe: From enrollment in the long-term follow-up study through 5 years of follow-up.
New Cancer Development
Timeframe: From enrollment in the long-term follow-up study through 5 years of follow-up.
Prostate Cancer Recurrence
Timeframe: From enrollment in the long-term follow-up study through 5 years of follow-up.